Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16280996 | 0.79 | KDM4E (0.42) | KDM4EFDPSTSHRCYP2C19 | |
| SCHEMBL1067575 | 0.78 | CPT2 (0.50) | KDM4EMMP8GRM2GRM3TSHR | |
| Hydrogen Peroxide SCHEMBL28864226 | 0.78 | CPT2 (0.50) | KDM4EMMP8GRM2GRM3TSHR | |
| SCHEMBL15080397 | 0.78 | ALDH1A1 (0.42) | KDM4EMMP8CYP2C19 | |
| SCHEMBL10538961 | 0.77 | FFAR1 (0.35) | KDM4E | |
| SCHEMBL22062527 | 0.77 | KDM4E (0.31) | KDM4ECYP2C19 | |
| SCHEMBL23679021 | 0.76 | — | — | |
| SCHEMBL6055135 | 0.76 | MMP8 (0.36) | MMP8GRM2GRM3TSHRCYP2C19 | |
| SCHEMBL10216230 | 0.76 | MMP8 (0.32) | MMP8CYP2C19 | |
| SCHEMBL12308797 | 0.76 | CTSD (0.37) | KDM4EMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097038-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES U.S. INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | MERSANA THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| EP-2758052-B9 | Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide | EURO CELTIQUE SA (LU) | 2019-03-27 | — | — | EP | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| EP-3318284-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN HDAC INHIBITOR AND A CYCLOPOLYSACCHARIDE | EURO-CELTIQUE S.A. (LU) | 2018-05-09 | — | — | EP | disclosed |
| EP-2758052-B1 | Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide | EURO CELTIQUE SA (LU) | 2018-02-14 | — | — | EP | disclosed |
| US-8017638-B2 | Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | SHIONOGI & CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| WO-2010085377-A2 | HYDROXAMIC ACID DERIVATIVES | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-4889946-A | Phenoxybenzoic acid compounds and herbicidal and plant growth regulant compositions | BAYER AKTIENGESELLSCHAFT (DE) | 1989-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | CD2BP2, DNPEP, LNPEP | KDM4E 3327/4885MMP8 1916/4885GRM2 3518/4885 |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | HSD3B1, NR5A1, HSD11B1 | KDM4E 2542/4885MMP8 2451/4885GRM2 1562/4885 |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | KDM4E 3327/4885MMP8 1916/4885GRM2 3518/4885 |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | GABRA4, GABRA1, GABRA2 | KDM4E 1256/4885MMP8 4591/4885GRM2 96/4885 |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | KDM4E 3327/4885MMP8 1916/4885GRM2 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.